Efficacy and Safety Overview

DUPIXENT demonstrated efficacy and safety across clinical trials

See how DUPIXENT reduced severe exacerbations, improved lung function,
reduced or eliminated OCS use, and has demonstrated safety profile.

DUPIXENT demonstrated efficacy and safety across clinical trials

See how DUPIXENT reduced severe exacerbations, improved lung function, reduced or eliminated OCS use, and has demonstrated safety profile.

Adults and Pediatric Patients (12+ Years)

icon-1

Exacerbations

Reduced severe
exacerbations by up to 81%1,a

SEE RESULTS
icon-2

Lung Function

Rapid and sustained
improvement in lung function
through 52 weeks1,b

SEE RESULTS
icon-3

OCS Reduction

Only biologic indicated
for OCS-dependent asthma
patients1

SEE RESULTS
icon-4

Quality of Life

Resulted in improved asthma
control and quality of life1,c,d

SEE RESULTS
icon-5

Safety Data

Demonstrated safety across 3
clinical trials1

SEE SAFETY DATA
icon-6

Study Designs

Studied up to 1 year in nearly
3000 asthma patients1

SEE STUDY DESIGNS
icon-4

TRAVERSE
Long-term Data

~3-year data across key
measures of asthma control1,2

SEE RESULTS

With DUPIXENT 300 mg + SOC (n=64) vs placebo + SOC (n=68) in annualized rate of severe exacerbations through Week 24 in patients with baseline blood eosinophils ≥300 cells/μL (DRI12544, secondary endpoint).1

470 mL improvement at Week 52 from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg + SOC (n=264) vs 170 mL improvement with placebo + SOC (n=148) (QUEST, EOS ≥300 cells/µL, secondary endpoint). ~72% of the total FEV1 improvement seen after the first dose at Week 2.1

75% of patients improved ACQ-5 (asthma control) score with DUPIXENT 200 mg + SOC vs 67% with placebo + SOC (OR: 1.46 [95% CI: 0.90, 2.35]) (QUEST, secondary endpoint).1

71% of patients improved AQLQ (quality of life) score with DUPIXENT 200 mg + SOC vs 55% with placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32]) (QUEST, secondary endpoint).1

Pediatric Patients (6-11 Years)

icon-4

Efficacy

Demonstrated data across
clinically meaningful
endpoints

SEE RESULTS
icon-5

Safety Data

Demonstrated safety profile
in pediatric patients (6-11
years) with asthma1

SEE RESULTS
icon-6

Study Designs

Studied up to 1 year in over
400 pediatric patients (6-11
years) with moderate-to-severe
asthma1

SEE RESULTS

ACQ-5. Asthma Control Questionnaire, 5-item version; AQLQ, Asthma Quality of Life Questionnaire; OR, odds ratio.